Coverage
-
October 24, 2011
Amgen Inc. said Monday it would pay $780 million to settle allegations over its sales and marketing practices stemming from civil and criminal investigations — including Medicaid claims and a whistleblower suit accusing the drugmaker of bribing health care providers to buy its drug Aranesp.
2 other articles on this case.
View all »